5:43 PM
 | 
Jul 26, 2013
 |  BC Extra  |  Company News

Gentium jump on CHMP reversal for Defitelio

Shares of Gentium S.p.A. (NASDAQ:GENT) jumped $4.85 (50%) to $14.61 on Friday after EMA's CHMP backed approval of Defitelio defibrotide to treat severe hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation therapy, reversing a prior negative recommendation. The...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >